NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Reviewed May 26, 2026

Ibandronate

Prescription ·Strong evidence ·Reviewed May 2026

Ibandronate is a bisphosphonate used for treatment and prevention of postmenopausal osteoporosis. Oral absorption is extremely low and is substantially reduced by food, beverages other than plain water, calcium, magnesium, iron, antacids, and vitamins, so strict fasting administration and mineral separation are essential.

What it's good for
  • Treatment of postmenopausal osteoporosis1,3
  • Prevention of postmenopausal osteoporosis1,2
  • Increased bone mineral density1,3
  • Reduced vertebral fracture risk1
What to watch for
  • Dyspepsia
  • Esophagitis
  • Esophageal ulcer
  • Esophageal abnormalities delaying emptying such as stricture or achalasia3
  • Inability to stand or sit upright for at least 60 minutes3

The bottom line

Evidence rating strong. Most-documented uses: treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, increased bone mineral density. 3 sources indexed (2004–2026), with 5 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Ibandronate binds hydroxyapatite at bone resorption surfaces and is taken up by osteoclasts during bone breakdown. As a nitrogen-containing bisphosphonate, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function and survival. Reduced osteoclast-mediated resorption increases bone mineral density and lowers vertebral fracture risk.1,3

Class
Bisphosphonate osteoporosis medication
Absorption
Best on an empty stomach
Dosing

Dosing & protocol.

Common range
Oral: 150 mg once monthly, taken first thing in the morning with plain water at least 60 minutes before food, drink, supplements, or other medications; older daily regimens used 2.5 mg daily. Intravenous: 3 mg every 3 months in appropriate patients.
Recommended form
Monthly oral tablet with strict administration instructions or supervised intravenous injection

Take oral ibandronate after an overnight fast with 6 to 8 ounces of plain water only. Remain upright and avoid food, beverages, supplements, and other medications for at least 60 minutes.

Safety

Full safety detail.

Side effects

  • Dyspepsia
  • Esophagitis
  • Esophageal ulcer
  • Abdominal pain
  • Musculoskeletal pain
  • Hypocalcemia
  • Influenza-like symptoms after IV dosing
  • Osteonecrosis of the jaw rarely
  • Atypical femur fracture with long-term use
  • Renal function concerns with IV therapy

Contraindications

  • Esophageal abnormalities delaying emptying such as stricture or achalasia3
  • Inability to stand or sit upright for at least 60 minutes3
  • Hypocalcemia3
  • Severe renal impairment3
  • Known hypersensitivity to ibandronate1,3
  • Correct calcium and vitamin D deficiency before treatment2,3
Interactions

Interaction records.

SeriousTiming Sensitive

Calcium

Calcium taken near oral ibandronate can markedly reduce absorption and treatment efficacy.

Recommendation: Take calcium later in the day, at least 60 minutes after ibandronate and preferably with a meal.

SeriousTiming Sensitive

Magnesium Glycinate

Magnesium can bind oral ibandronate and reduce its already very low bioavailability.

Recommendation: Avoid magnesium before and for at least 60 minutes after ibandronate; later-day dosing is preferred.

SeriousTiming Sensitive

Iron

Iron supplements can chelate ibandronate and reduce absorption.

Recommendation: Take iron at a different time of day, not during the fasting ibandronate window.

ModerateTiming Sensitive

Zinc

Zinc may bind oral ibandronate and reduce absorption if taken too close.

Recommendation: Separate zinc from ibandronate by at least 60 minutes, and ideally take zinc later with food.

InfoSynergy

Vitamin D3

Adequate vitamin D supports safe and effective antiresorptive therapy by reducing hypocalcemia risk and supporting bone mineralization.

Recommendation: Correct vitamin D deficiency before or during therapy under clinician guidance.

Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Randomized controlled trials

1
  • 1Oral ibandronate significantly reduces the risk of vertebral fractures of postmenopausal osteoporosisNeeds reviewNo linkChesnut CH et al. · Journal of Bone and Mineral Research · 2004

    Pivotal fracture trial supports vertebral fracture reduction and bone density improvement.

Reviews & position papers

1
  • 2Clinician's Guide to Prevention and Treatment of OsteoporosisNeeds reviewNo linkLeBoff MS et al. · Osteoporosis International · 2022

    Guideline supports bisphosphonates for high-risk patients and adequate calcium and vitamin D intake.

Reference material

1
  • 3Ibandronate Sodium Tablets US Prescribing InformationNeeds reviewURLU.S. National Library of Medicine · DailyMed · 2026

    Labeling describes monthly fasting dosing, 60-minute upright requirement, mineral separation, hypocalcemia correction, renal limits, and esophageal warnings.

Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Ibandronate in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.